Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Sells $211,477.86 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) General Counsel Junlin Ho sold 5,742 shares of Scholar Rock stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $211,477.86. Following the completion of the sale, the general counsel now owns 189,295 shares of the company's stock, valued at approximately $6,971,734.85. This trade represents a 2.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Junlin Ho also recently made the following trade(s):

• On Thursday, January 16th, Junlin Ho sold 9,039 shares of Scholar Rock stock. The stock was sold at an average price of $44.20, for a total transaction of $399,523.80.

Scholar Rock Trading Down 3.7 %

NASDAQ SRRK traded down $1.45 on Friday, hitting $37.70. 717,240 shares of the company were exchanged, compared to its average volume of 757,555. The firm has a market capitalization of $3.53 billion, a P/E ratio of -16.04 and a beta of 0.50. Scholar Rock Holding Co. has a twelve month low of $6.76 and a twelve month high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The company's 50 day moving average price is $41.81 and its 200-day moving average price is $28.37.

Analyst Upgrades and Downgrades

SRRK has been the subject of a number of research reports. Wedbush reaffirmed an "outperform" rating and issued a $47.00 price objective on shares of Scholar Rock in a report on Wednesday, January 29th. HC Wainwright lifted their price objective on shares of Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Finally, Truist Financial lifted their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, November 25th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Scholar Rock has an average rating of "Buy" and an average target price of $40.43.

Hedge Funds Weigh In On Scholar Rock

A number of large investors have recently made changes to their positions in SRRK. Wellington Management Group LLP grew its stake in shares of Scholar Rock by 16.2% in the 3rd quarter. Wellington Management Group LLP now owns 199,777 shares of the company's stock valued at $1,600,000 after buying an additional 27,801 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Scholar Rock by 9.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company's stock valued at $4,027,000 after buying an additional 42,139 shares in the last quarter. Barclays PLC grew its stake in shares of Scholar Rock by 103.4% in the 3rd quarter. Barclays PLC now owns 165,449 shares of the company's stock valued at $1,324,000 after buying an additional 84,118 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Scholar Rock by 7.1% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company's stock valued at $759,000 after buying an additional 6,269 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Scholar Rock by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock valued at $12,361,000 after buying an additional 120,489 shares in the last quarter. Institutional investors and hedge funds own 91.08% of the company's stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.